Appeal No. 1997-1987
Application No. 08/108,005
group consisting of subacute encephalitis associated with
dementia and vacuolar myelopathies. The method comprises
administering to a patient in need thereof a therapeutically
effective amount of at least one member selected from the
group consisting of S-adenosyl-methionine salt, 5-
methyltetrahydrofolic acid and 5-formyltetrahydrofolic acid.
2. Anticipation under 35 U.S.C. § 102 requires a prior
art reference to disclose each and every element set forth in
the claims. See RCA Corp. v. Applied Digital Data System,
Inc., 730 F.2d 1440, 1444, 221 USPQ 385, 388 (Fed. Cir. 1984).
3. Le Grazie discloses a therapeutic method for treating
organic mental disorders, in particular senile and presenile
primary degenerative Alzheimer dementia and multiinfarctual
dementia. The method comprises orally administering a
therapeu-tically effective amount of 5-methyl-tetrahydrofolic
acid or 5-formyl-tetrahydrofolic acid or a pharmaceutically
acceptable salt thereof in a controlled release form. Le
Grazie, col. 1, lines 11-21, col. 2, lines 7-46. However, Le
Grazie does not disclose treating a patient afflicted with
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007